Supplement for Zika Response, a Single-Award Deviation From Competition Requirements for the National Center for Medical Home Implementation Cooperative Agreement, 66040-66041 [2016-23096]
Download as PDF
<![CDATA[
66040
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
In the
Federal Register of Monday, September
19, 2016, in FR Doc. 2016–22470, on
page 64178 the following correction is
made:
On page 64178, in the second column,
in the last sentence of the first
paragraph under Section I, Background,
‘‘Biomarkers Used as Outcomes in
Development of FDA-Approved
Therapeutics (October 2007 to
December 2015)’’ is corrected to read
‘‘https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/Drug
DevelopmentToolsQualification
Program/ucm483052.htm’’.
SUPPLEMENTARY INFORMATION:
Dated: September 21, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–23106 Filed 9–23–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Supplement for Zika Response, a
Single-Award Deviation From
Competition Requirements for the
National Center for Medical Home
Implementation Cooperative
Agreement
Authority: Social Security Act, Title V,
sections 501(a)(1)(D) and 501(a)(2), (42 U.S.C.
701(a)(1)(D) and 701(a)(2))
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
HRSA announces the award
of a supplement in the amount of
$350,000 for the National Center for
Medical Home Implementation
(NCMHI) cooperative agreement. The
purpose of the NCMHI cooperative
agreement is to support a national
resource and assistance effort to
implement and spread the medical
home model to all children and youth,
particularly children with special health
care needs (CSHCN), children who are
vulnerable and/or medically
underserved, and pediatric populations
served by state public health programs,
SUMMARY:
the Maternal and Child Health Bureau
(MCHB), and HRSA. The supplement
will permit the American Academy of
Pediatrics (AAP), the cooperative
agreement awardee, during the budget
period of July 1, 2016–June 30, 2017, to
enhance their capacity to provide
technical assistance and health
professional education to increase the
clinical expertise of pediatric health
care professionals, including safety net
providers, to more effectively serve as
the medical home and provide familycentered, comprehensive, coordinated,
and culturally-effective care for Zikaaffected children and their families.
FOR FURTHER INFORMATION CONTACT:
Marie Y. Mann, MD, MPH, FAAP,
Division of Services for Children with
Special Health Needs, Maternal and
Child Health Bureau, Health Resources
and Services Administration, 5600
Fishers Lane, Room 18W61, Rockville,
Maryland 20857; MMann@hrsa.gov.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award: The
American Academy of Pediatrics.
Amount of Non-Competitive Awards:
$350,000.
Period of Supplemental Funding:
7/1/2016–6/30/2017.
CFDA Number: 93.110.
Justification: Zika virus infection
during pregnancy dramatically increases
the risk of birth defects. Microcephaly
has been linked to Zika virus infection
during pregnancy, and the extent of
other possible birth defects is unclear.
As of August 25, 2016, there are 624
pregnant women in the 50 states and the
District of Columbia reported to have
the Zika virus infection. In Puerto Rico,
over 600 pregnant women have been
reported to have the Zika virus infection
as a result of exposure to the Zika virus
during pregnancy. However, pediatric
specialty expertise to care for their
babies is limited. Currently, no network
exists to link providers caring for these
patients with those who have relevant
expertise or experience in managing
infants and children of women exposed
to Zika virus during pregnancy.
Discussions of developmental screening,
clinical management, and family
support approaches will help clinicians
serving this population, thereby
increasing access to well-coordinated,
family-centered care and management
in a medical home for children and
families impacted by Zika-related
complications.
The purpose of the NCMHI
cooperative agreement is to support a
national resource and assistance effort
to implement and spread the medical
home model to all children and youth,
particularly CSHCN, children who are
vulnerable and/or medically
underserved, and pediatric populations
served by state public health programs,
MCHB, and HRSA. In 2013, following
objective review of its competitive
application, HRSA awarded the NCMHI
cooperative agreement to AAP, a
nonprofit, tax-exempt organization
under Internal Revenue Code 501(c)(3).
This supplement to the NCMHI
cooperative agreement provides
technical assistance and education,
including tele-mentoring, to clinicians
providing care for children who are or
may be impacted by Zika at HRSAsupported health centers and elsewhere
within the United States (including U.S.
territories and jurisdictions). Using the
tele-mentoring technology, clinicians
will team with specialists elsewhere to
provide clinicians with the tools and
resources to improve care delivery
within the medical home, thereby
increasing the sustainability of the
medical home model for children
affected by Zika. Though available to all
clinicians, technical assistance and
education will be directed primarily
toward pediatric primary care
physicians in areas at high-risk for Zika
and toward clinicians operating in
health centers supported by HRSA’s
Bureau of Primary Health Care. These
activities will provide critical
knowledge to health care professionals,
including safety net providers, to more
effectively serve as the medical home
for children affected by Zika and their
families.
mstockstill on DSK3G9T082PROD with NOTICES
Grantee/organization name
Grant No.
State
FY 2016
authorized
funding level
FY 2016
estimated
funding for this
supplement
The American Academy of Pediatrics .............................................................
U43MC09134
IL
$1,300,031
$350,000
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
E:\FR\FM\26SEN1.SGM
26SEN1
Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices
Dated: September 19, 2016.
James Macrae,
Acting Administrator.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2016–23096 Filed 9–23–16; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy And
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK3G9T082PROD with NOTICES
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: October 18, 2016.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities/
Room 3G31B, National Institutes of Health,
NIAID, 5601 Fishers Lane MSC 9823,
Rockville, MD 20892, (240) 669–5060,
james.snyder@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23139 Filed 9–23–16; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; RAPID ASSESSMENT OF
ZIKA VIRUS (ZIKV) COMPLICATIONS
(R21).
Date: October 20, 2016.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Jay R. Radke, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3G11B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC–9823,
Bethesda, MD 20892–9823, (240) 669–5046,
jay.radke@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 21, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23142 Filed 9–23–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
VerDate Sep<11>2014
19:40 Sep 23, 2016
Jkt 238001
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
66041
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Allergy, Immunology,
and Transplantation Research Committee.
Date: October 20, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: James T. Snyder, Ph.D.,
Scientific Review Officer Scientific Review
Program, Division of Extramural Activities/
Room 3G31B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892–9834, (240) 669–5060,
james.snyder@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 19, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–23140 Filed 9–23–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute, Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Heart, Lung, and Blood
Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
E:\FR\FM\26SEN1.SGM
26SEN1
]]>Agencies
[Federal Register Volume 81, Number 186 (Monday, September 26, 2016)]
[Notices]
[Pages 66040-66041]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Supplement for Zika Response, a Single-Award Deviation From
Competition Requirements for the National Center for Medical Home
Implementation Cooperative Agreement
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: HRSA announces the award of a supplement in the amount of
$350,000 for the National Center for Medical Home Implementation
(NCMHI) cooperative agreement. The purpose of the NCMHI cooperative
agreement is to support a national resource and assistance effort to
implement and spread the medical home model to all children and youth,
particularly children with special health care needs (CSHCN), children
who are vulnerable and/or medically underserved, and pediatric
populations served by state public health programs, the Maternal and
Child Health Bureau (MCHB), and HRSA. The supplement will permit the
American Academy of Pediatrics (AAP), the cooperative agreement
awardee, during the budget period of July 1, 2016-June 30, 2017, to
enhance their capacity to provide technical assistance and health
professional education to increase the clinical expertise of pediatric
health care professionals, including safety net providers, to more
effectively serve as the medical home and provide family-centered,
comprehensive, coordinated, and culturally-effective care for Zika-
affected children and their families.
FOR FURTHER INFORMATION CONTACT: Marie Y. Mann, MD, MPH, FAAP, Division
of Services for Children with Special Health Needs, Maternal and Child
Health Bureau, Health Resources and Services Administration, 5600
Fishers Lane, Room 18W61, Rockville, Maryland 20857; MMann@hrsa.gov.
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award: The American Academy of
Pediatrics.
Amount of Non-Competitive Awards: $350,000.
Period of Supplemental Funding: 7/1/2016-6/30/2017.
CFDA Number: 93.110.
Authority: Social Security Act, Title V, sections 501(a)(1)(D)
and 501(a)(2), (42 U.S.C. 701(a)(1)(D) and 701(a)(2))
Justification: Zika virus infection during pregnancy dramatically
increases the risk of birth defects. Microcephaly has been linked to
Zika virus infection during pregnancy, and the extent of other possible
birth defects is unclear. As of August 25, 2016, there are 624 pregnant
women in the 50 states and the District of Columbia reported to have
the Zika virus infection. In Puerto Rico, over 600 pregnant women have
been reported to have the Zika virus infection as a result of exposure
to the Zika virus during pregnancy. However, pediatric specialty
expertise to care for their babies is limited. Currently, no network
exists to link providers caring for these patients with those who have
relevant expertise or experience in managing infants and children of
women exposed to Zika virus during pregnancy. Discussions of
developmental screening, clinical management, and family support
approaches will help clinicians serving this population, thereby
increasing access to well-coordinated, family-centered care and
management in a medical home for children and families impacted by
Zika-related complications.
The purpose of the NCMHI cooperative agreement is to support a
national resource and assistance effort to implement and spread the
medical home model to all children and youth, particularly CSHCN,
children who are vulnerable and/or medically underserved, and pediatric
populations served by state public health programs, MCHB, and HRSA. In
2013, following objective review of its competitive application, HRSA
awarded the NCMHI cooperative agreement to AAP, a nonprofit, tax-exempt
organization under Internal Revenue Code 501(c)(3).
This supplement to the NCMHI cooperative agreement provides
technical assistance and education, including tele-mentoring, to
clinicians providing care for children who are or may be impacted by
Zika at HRSA-supported health centers and elsewhere within the United
States (including U.S. territories and jurisdictions). Using the tele-
mentoring technology, clinicians will team with specialists elsewhere
to provide clinicians with the tools and resources to improve care
delivery within the medical home, thereby increasing the sustainability
of the medical home model for children affected by Zika. Though
available to all clinicians, technical assistance and education will be
directed primarily toward pediatric primary care physicians in areas at
high-risk for Zika and toward clinicians operating in health centers
supported by HRSA's Bureau of Primary Health Care. These activities
will provide critical knowledge to health care professionals, including
safety net providers, to more effectively serve as the medical home for
children affected by Zika and their families.
----------------------------------------------------------------------------------------------------------------
FY 2016
FY 2016 estimated
Grantee/organization name Grant No. State authorized funding for
funding level this supplement
----------------------------------------------------------------------------------------------------------------
The American Academy of Pediatrics.......... U43MC09134 IL $1,300,031 $350,000
----------------------------------------------------------------------------------------------------------------
[[Page 66041]]
Dated: September 19, 2016.
James Macrae,
Acting Administrator.
[FR Doc. 2016-23096 Filed 9-23-16; 8:45 am]
BILLING CODE 4165-15-P
